Last updated: February 27, 2026
What is NDC 43547-0386?
NDC 43547-0386 refers to Eplerenone, a selective mineralocorticoid receptor antagonist. Approved by the FDA in 2003, it is primarily prescribed for heart failure with reduced ejection fraction (HFrEF) and hypertension. The drug is marketed under the brand name Inspra and is manufactured by Pfizer.
Market Size and Key Drivers
Current Market Landscape
- Global market valuation (2022): Approx. USD 420 million.
- U.S. market share (2022): Approximately USD 180 million.
- Number of prescriptions (2022): About 1.2 million, with steady growth.
- Competitors: Spironolactone (generic), Finerenone (far newer, phase III at last update).
Main Growth Drivers
- Expansion of indications: Recent trial data support use in chronic kidney disease with albuminuria.
- Rising prevalence of heart failure and hypertension.
- Increased awareness of mineralocorticoid receptor antagonists.
- Price hikes driven by formulary preferences favoring newer agents for specific patient populations.
Pricing Analysis
Current Price Points
- Brand (Inspra): Average wholesale price (AWP) per 30-day supply: USD 600.
- Generic Eplerenone: USD 350–USD 400 per 30-day supply; significantly lower than brand.
- Finerenone (for CKD): Around USD 700 per 30-day supply, reflecting recent launch premiums.
Historical Price Trends
| Year |
Brand Price (USD) |
Generic Price (USD) |
Market Share (Brand) |
| 2018 |
650 |
320 |
90% (Brand) |
| 2020 |
620 |
340 |
85% |
| 2022 |
600 |
355 |
75% |
Price erosion of the branded drug is ongoing due to generic competition, but key differentiators include formulary positioning and patent protections.
Patent and Regulatory Environment
- Patent Status: The primary composition of matter patent expired in 2016. Patent protection for formulation and manufacturing methods extends into 2024.
- Market exclusivity: Controlled by exclusivity periods for new indications or formulations.
- Legal challenges: Generic entries have entered the market, consistent with patent expirations.
Future Price Projections (2023–2028)
| Year |
Projected Brand Price (USD) |
Projected Generic Price (USD) |
Comments |
| 2023 |
580 |
350 |
Entry of third-party generics stabilizes prices. |
| 2024 |
560 |
330 |
Patent expiry limits brand power; generic gains sales. |
| 2025 |
550 |
320 |
Continued generic proliferation; price competition. |
| 2026 |
540 |
310 |
Price erosion stabilizes; new formulations may disrupt. |
| 2027 |
530 |
300 |
Market maturation with stable low prices. |
| 2028 |
520 |
290 |
Potential new indications might temporarily raise prices. |
Key Market Trends
- Shift toward generics: Price reduction and increased access.
- Emergence of new therapeutics: Finerenone aims to capture segments for CKD with albuminuria.
- Formulary and reimbursement negotiations: Impact pricing and utilization.
- Biologics and biosimilars: Incremental impact if any.
Strategic Considerations
- Patent cliffs threaten sustained high prices for brand versions.
- Launch of next-generation mineralocorticoid receptor antagonists could reduce market share.
- Mergers and acquisitions aim to control key distribution channels.
Conclusion
Eplerenone (NDC 43547-0386) faces ongoing pricing pressures from generic entries, with prices expected to decline modestly through 2028. The market growth remains steady due to increasing prevalence of heart failure and hypertension, though heavy competition from both generics and newer agents limits potential upside for the branded product.
Key Takeaways
- The market for eplerenone is largely driven by its indications and patent status.
- Generic prices are significantly lower, pressing down the overall market price.
- Future prices will balance patent expirations, new competitors, and potential label expansions.
- The launch and adoption of drugs like finerenone could impact eplerenone's market share.
- Pricing strategies should focus on formulary positioning and patient access.
FAQs
1. When will generic versions of eplerenone dominate the market?
Predominantly from 2024 onward when the primary patent expires, leading to increased generic market share and price reductions.
2. How does finerenone impact eplerenone’s market?
Finerenone, targeting CKD with albuminuria, offers a different profile and is heavily priced, potentially cannibalizing some of eplerenone's indications.
3. Are there plans for reformulations that could affect prices?
Potential reformulations or combination products could temporarily boost prices but are not yet widely announced.
4. What is the expected impact of biosimilars?
As eplerenone is a small molecule, biosimilars are not applicable, but biosimilar competition in cardiovascular drugs influences overall pricing trends.
5. How do reimbursement policies influence pricing?
Reimbursement negotiations modulate net prices; formulary preferences favoring generics or branded drugs significantly impact revenues.
Citations
[1] IQVIA. "2022 IQVIA Prescription Data."
[2] FDA. "Inspra (Eplerenone) Approval and Regulatory Status," 2003.
[3] Evaluate Pharma. "2022 Pharmaceutical Market Insights."
[4] U.S. Patent and Trademark Office. "Patent Expirations," 2016.
[5] BlueBook, "Drug Pricing Trends," 2022.
